Category - Developments

Developments

Kane Biotech gets $3.8-million Canadian government funding

Kane Biotech (TSXV:KNE) received $3.8-million in funding from Western Economic Diversification Canada to assist the company in expanding from the animal health sector into the human health sector with DispersinB, a...

August 6, 2019

Developments

Eloxx Pharma initiates Phase 2 cystinosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX) initiated a Phase 2 trial of ELX-02 for the treatment of nephropathic cystinosis. Cystinosis is a genetic disease caused by a mutation in the cystinosin gene, which limits production...

August 6, 2019

Developments

SELLAS completes enrollment for Phase 2 DCIS trial

SELLAS Life Sciences Group (NASDAQ:SLS) completed enrollment for a Phase 2 study of nelipepimut-S (NPS) in combination with granulocyte macrophage colony stimulating factor (GM-CSF) in women with ductal carcinoma in...

August 6, 2019

Developments

FDA clears Mustang Bio IND for CAR T cell therapy

Mustang Bio (NASDAQ:MBIO) reported that the FDA approved its IND application for MB-102 for the treatment of acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk...

August 6, 2019

Developments

Provention Bio gets FDA breakthrough therapy designation for PRV-031

Provention Bio (NASDAQ:PRVB) received breakthrough therapy designation for PRV-031 for the prevention or delay of Type 1 diabetes (T1D) in at-risk individuals. PRV-031, an anti-CD3 monoclonal antibody also known as...

August 6, 2019

Developments

Knight expands reimbursement for Titan Pharma’s Probuphine in Canada

Knight Therapeutics (TSX:GUD) reached agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for a letter of intent covering reimbursement of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first...

August 6, 2019

Developments

MD Anderson initiates pancreatic cancer trial of Soricimed’s SOR-C13

The University of Texas MD Anderson Cancer Center activated an investigator- initiated Phase 1b clinical trial of Soricimed Biopharma’s lead drug candidate, SOR-C13, in late-stage pancreatic cancer. The objectives of...

August 6, 2019

Developments

Zenabis receives cultivation license for Langley plant upping capacity by 30%

Zenabis Global (TSX:ZENA) received a cultivation license from Health Canada for its Zenabis Langley plant, adding 9,900 kg of licensed annual cultivation capacity of cannabis at Site A – Part 1 at the facility. The...

August 6, 2019

Developments

AC Immune initiates Phase 1b/2a trial of Alzheimer’s disease vaccine

AC Immune (NASDAQ:ACIU) initiated a Phase 1b/2a clinical trial to evaluate its anti-phospho-Tau vaccine in patients with early Alzheimer’s disease (AD). Targeting pathological Tau, the vaccine is intended as a disease...

August 1, 2019

Developments

X4 Pharma’s mavorixafor gets EC orphan drug designation for WHIM syndrome

The European Commission (EC) granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor orphan drug designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and...

August 1, 2019

Category - Developments

Subscribe